Schedule 13G ownership disclosure

NextCure Inc

Common Stock, par value $0.001 per share · CUSIP: 65343E207

Event date: 2025-06-20

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Simcere Zaiming, Inc.

    Shares: 338,636.00 · Class: 12.7%

  • Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

    Shares: 338,636.00 · Class: 12.7%

  • Hainan Simcere Zaiming Pharmaceutical Co., Ltd.

    Shares: 338,636.00 · Class: 12.7%

  • Simcere Pharmaceutical Group Limited

    Shares: 338,636.00 · Class: 12.7%

  • Ren Jinsheng

    Shares: 338,636.00 · Class: 12.7%

  • Tang Renhong

    Shares: 338,636.00 · Class: 12.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-078679
Form type
SCHEDULE 13G
Filer
NextCure, Inc.
CIK
CIK 1661059
Filed
Aug 19, 2025
Reporting period
Jun 20, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub